• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Meta-Analysis: Does Vaginal Progesterone Reduce the Risk of Recurrent Preterm Birth?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Evidence regarding the efficacy of vaginal progesterone for preterm birth prevention is conflicting
  • Conde-Agudelo et al. (AJOG, 2022) assessed the efficacy and safety of vaginal progesterone to prevent recurrent preterm birth and adverse perinatal outcomes in singleton gestations  

METHODS:

  • Systematic review and meta-analysis
  • Study inclusion criteria
    • RCTs
    • Asymptomatic women with a singleton gestation and a history of spontaneous preterm birth
    • Comparison of vaginal progesterone to placebo or no treatment
  • Study design
    • Pooled relative risk (RR) were estimated
    • Risk of bias and quality of evidence were assessed
    • Subgroup analyses were performed
  • Primary outcomes
    • Preterm birth <37 and <34 weeks
  • Secondary outcomes
    • Adverse maternal and perinatal outcomes

RESULTS:

  • 10 studies | 2958 women
    • Small studies (sample size <150): 7
      • High risk of bias: 4
    • Large studies (samples size >600): 3
      • High risk of bias: none
  • Vaginal progesterone significantly decreased the risk of
    • Preterm birth at 37 weeks
      • RR 0.64 (95% CI, 0.50 to 0.81)
      • 95% prediction interval 0.31 to 1.32
      • Very low-quality evidence
    • Preterm birth <34 weeks
      • RR 0.62 (95% CI, 0.42 to 0.92)
      • 95% prediction interval 0.23 to 1.68
      • Very low-quality evidence
    • NICU Admission
      • RR 0.53 (95% CI, 0.33 to 0.85)
      • 95% prediction interval 0.16 to 1.79
      • Low-quality evidence
  • There were no significant differences between the vaginal progesterone and the placebo or no treatment groups for other adverse perinatal and maternal outcomes
  • Subgroup analyses revealed that vaginal progesterone decreased the risk of preterm birth in small studies, but not large studies
    • Preterm birth <37 weeks
      • Small studies: RR 0.43 (95% CI, 0.33 to 0.55)
      • Large studies: RR 0.98 (95% CI, 0.88 to 1.09)
    • Preterm birth <34 weeks
      • Small studies: RR 0.27 (95% CI, 0.15 to 0.49)
      • Large studies: RR 0.94 (95% CI, 0.78 to 1.13)
  • Analyses restricted to studies at low risk of bias indicated that vaginal progesterone did not reduce the risk of preterm birth
    • Preterm birth <37 weeks: RR 0.96 (95% CI, 0.84 to 1.09)
    • Preterm birth <34 weeks: RR 0.90 (95% CI, 0.71 to 1.15)
  • Small-study effects (when small trials report larger benefits of treatment than large trials)
    • Found to be present in the meta-analyses of preterm birth <37 and <34 weeks
  • The adjustment for small-study effects resulted in a markedly reduced and nonsignificant effect of vaginal progesterone on preterm birth
    • Preterm birth <37 weeks: RR 0.86 (95% CI, 0.68 to 1.10)
    • Preterm birth <34 weeks: RR 0.92 (95% CI, 0.60 to 1.42)

CONCLUSION:

  • Vaginal progesterone did not reduce the risk of recurrent preterm birth for women with singleton gestations and a history of preterm birth
  • The authors state

In summary, there is persuasive evidence that small-study effects in the meta-analyses of the effect of vaginal progesterone on preterm birth <37 and <34 weeks of gestation are mainly explained by the poor methodological quality of most small trials

Learn More – Primary Sources:

Does vaginal progesterone prevent recurrent preterm birth in women with a singleton gestation and a history of spontaneous preterm birth? Evidence from a systematic review and meta-analysis

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

RCT Results: Vaginal Progesterone or 17-OHPC for Preventing Recurrent Preterm Birth?
EPPPIC Meta-analysis Results: Progestogens for Preterm Birth Prevention

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site